ClinicalTrials.gg
Active, not recruitingNCT06288230Updated Jun 15, 2026

An Open Label Study of Gene Therapy Product (Vesemnogene Lantuparvovec) in Spinal Muscular Atrophy

A Phase 1/2 interventional study of vesemnogene lantuparvovec in Spinal Muscular Atrophy, sponsored by Lantu Biopharma. Active, not recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by Lantu Biopharma · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 23 studies in Muscular Atrophy, Spinal with a site in China — 6 open to participants now, 13 under way, 4 of them phase 3. Muscular Atrophy, Spinal · China.

Planned enrollment
11th of 16
20 · median 35
Started
2024
with 1 other
Phase 1/2
2 of 23
1 open now
Primary completion
2027-10
later than 5 of 12 live
Registered
15th of 23
by date
Lead sponsor
1 of 23
Lantu Biopharma

Among the 23 studies in Muscular Atrophy, Spinal with a site in China, this one is the 11th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2024, is one of 2 in phase 1/2, reaches primary completion later than 5 of the 12 other live ones, and was the 15th registered.

Muscular Atrophy, Spinal

282 studies on the registry are indexed under Muscular Atrophy, Spinal; 71 are open to participants now.

Browse Muscular Atrophy, Spinal studies →

Open to participants now

6 of the 23 studies in Muscular Atrophy, Spinal with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 56 Muscular Atrophy, Spinal studies recruiting now, 28 (50%) set no upper age limit and 25 (45%) stop at 75 or younger; 44 take children under 18; 11 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Muscular Atrophy, Spinal with a site in China, or all of them as a file.
02

Study summary

This is an interventional study to evaluate safety and efficacy of AAV-hSMN1 in spinal muscular atrophy patients.

Read the detailed description

Study duration per participant is approximately 25 months including an approximately 30-day screening/baseline period, an approximately 24-month study observation period including 1 treatment day, and an approximately 24-month follow-up period. Patients will be stratified in two groups, those \< 24 months of age at time of dosing and those ≥ 24 months of age at time of dosing. This study will be conducted in 2 stages:

Stage 1: dose escalting study in children \<24 months of age. Stage 2: the selecetd dose from Stage 1 in children ≥ 24 months of age.

Patients will be tested at baseline and return for follow-up visits twice a week through the first month post dose, and followed by visits at months 2, 3, 6 12, 18 and 24 post infusion. Unscheduled visits may occur if the investigator determines that they are necessary.

For patients enrolled from overseas, follow-up visits with patient's own paediatrician together with remote virtual visits are allowed.

03

Conditions studied

  • Spinal Muscular Atrophy
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of SMA based on gene mutation analysis with bi-allelic survival motor neuron (SMN1) mutations (deletion or point mutations).
  • Patients or Parent(s)/legal guardian(s) willing and able to complete the process and comply with study procedures and visit schedule.

Exclusion criteria

Exclusion Criteria:

  • Anti-AAV9 antibody titers >1:20 as determined by Enzyme-linked Immunosorbent Assay (ELISA) binding immunoassay.
  • Active viral infection (includes or serology positive for or C).
  • Use of invasive ventilatory support (tracheotomy with positive pressure) or pulse oximetry \<95% saturation.
  • Concomitant illness and any drug that in the opinion of the investigator creates unnecessary risks for gene transfer.
  • abnormal laboratory values.
  • Participation in a recent SMA treatment clinical trial that in the opinion of the PI creates unnecessary risks for gene transfer.
  • Patient with signs of aspiration based on a swallowing test and unwilling to use an alternative method to oral feeding.
  • For children ≥ 24 months of age, for spinal tap procedure or administration of intrathecal therapy or presence of an implanted shunt for the drainage of CSF or an implanted central venous (CNS) catheter.
  • For children ≥ 24 months of age, severe contractures as determined by Physical Therapist(s) at screening that interfere with either the ability to attain/demonstrate functional measures or interferes with ability to receive dosing.
  • For children ≥ 24 months of age, severe scoliosis (defined as ≥ 50° curvature of spine) evident on X-ray examination.
  • For children ≥ 24 months of age, previous, planned or expected scoliosis repair surgery/procedure within 1 year of dose administration.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Stage 1: Dose A in children < 24 months of age

    Dose escalting study: Administration Dose A of Vesemnogene Lantuparvovec in children \< 24 months of age

    Biological: vesemnogene lantuparvovec

  • Experimental
    Stage 1: Dose B in children < 24 months of age

    Dose escalting study: Administration Dose B of Vesemnogene Lantuparvovec in children \< 24 months of age

    Biological: vesemnogene lantuparvovec

  • Experimental
    Stage 2: The selected dose in children ≥ 24 months of age

    Administration the selected dose of Vesemnogene Lantuparvovec in children ≥ 24 months of age

    Biological: vesemnogene lantuparvovec

Interventions

  • Biologicalvesemnogene lantuparvovec

    Exploratory study evaluating the safety and efficacy of vesemnogene lantuparvovec in patients with SMA.

    Also known as: AAV-hSMN1

06

What researchers measure

Primary outcomes

  1. Numbers of participants with adverse events (AEs), serious adverse events (SAEs)

    Participants are monitored for safety from baseline up to the end of the follow-up period.

    Time frame: Baseline up to 24 months

Secondary outcomes

  1. Change from baseline in developmental gross motor milestones achieved according to WHO criteria

    For patients with SMA, the percentage of participants who are able to preserve ambulatory function.

    Time frame: Baseline up to 24 months

  2. Change from baseline in CHOP-INTEND in children <24 months of age

    The CHOP-INTEND contains 16 items rated from 0 to 4. Total scores range from 0-64. Higher scores indicate higher levels of motor ability.

    Time frame: Baseline up to 24 months

  3. Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) in children ≥ 24 months of age

    The HFMSE contains 33 items rated from 0 (unable to perform) to 2 (performs without modification/adaptation/compensation). Total scores range from 0-66. Higher scores indicate higher levels of motor ability.

    Time frame: Baseline up to 24 months

07

Study locations

1 site
  • Kunming Hope of Health Hospital
    Kunming, Yunnan 650200, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for Oct 2027, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2024
First posted
Mar 1, 2024
StartActual
Oct 20, 2024
Primary completionEst.
Oct 30, 2027
CompletionEst.
Oct 30, 2027
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06288230
Lead sponsor
Lantu Biopharma
Responsible party
Sponsor
First posted
Mar 1, 2024
Start date
Oct 20, 2024
Primary completion
Oct 30, 2027 (estimated)
Completion
Oct 30, 2027 (estimated)
Last update
Jun 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion